Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308472 · ClinicalTrials.gov registry record · Phase 2
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
A Phase 2 study, sponsored by Disc Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT05308472 is a Phase 2 study that has completed, run by Disc Medicine. The registered enrollment target is 75 participants.
The verdict
NCT05308472, a Phase 2 study, has completed, sponsored by Disc Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.
Interventions
- DRUG Placebo
- DRUG DISC-1459
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2024-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05308472
The ClinicalTrials.gov registry entry for NCT05308472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Disc Medicine, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05308472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05308472 about?
NCT05308472 is a clinical study titled "Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP". This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blin...
What is the current status of trial NCT05308472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2022-10-31. Estimated completion is 2024-08-23.
What interventions are being tested in trial NCT05308472?
The interventions under investigation include: Placebo (DRUG), DISC-1459 (DRUG).
Who is sponsoring clinical trial NCT05308472?
This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.